HT
BBIO icon

Headlands Technologies’s BridgeBio Pharma BBIO Stock Holding History

Headlands Technologies’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-1,905
Closed -$48.3K – 1190
2024
Q2 		$48.3K Buy
+1,905
New +$52.1K 0.01% 772
2023
Q3 		– Sell
-6,324
Closed -$109K – 927
2023
Q2 		$109K Buy
+6,324
New +$95.2K 0.03% 371

Other funds holding BBIO

KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Headlands Technologies's BBIO Position: Q3 2024 in Review

Headlands Technologies sold out of BridgeBio Pharma (BBIO) in Q3 2024, closing a stake of 1,905 shares — an estimated $48.3K sold.

Headlands Technologies first reported a position in BBIO in Q2 2023 and held it in 2 quarters. The position peaked at $109K in Q2 2023. 253 funds tracked by Wall St. Rank hold BBIO as of Q3 2024.

  • Headlands Technologies reported no remaining BridgeBio Pharma position as of Q3 2024 after selling out during the quarter.
  • Headlands Technologies sold 1,905 BridgeBio Pharma shares in Q3 2024, an estimated $48.3K.
  • Headlands Technologies first reported a position in BridgeBio Pharma in Q2 2023 and held it in 2 quarters.
  • Headlands Technologies's BridgeBio Pharma position peaked at $109K in Q2 2023.
  • 253 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q3 2024.

Based on Headlands Technologies's 13F filing for Q3 2024, filed 12 Nov 2024.